Zobrazeno 1 - 4
of 4
pro vyhledávání: '"R M Saiz Chumillas"'
Autor:
R M Saiz Chumillas, L Alba, Y Gonzalez-Lama, B Velayos, P Suarez, C Maroto-Martin, A Nuñez, L Hernandez, L Relea, L Fernandez-Salazar, M Sierra-Ausin, J Barrio, F Muñoz, L Arias, B Sicilia
Publikováno v:
Journal of Crohn's and Colitis. 16:i211-i213
Background The 21st century has witnessed advances in endoscopic surveillance technology such as high-definition imaging and virtual or dye-based chromoendoscopy, which have led to increased detection of dysplasia. It is unknown the rates of new dysp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb2c54eb61890c959083815c0fd7463e
https://doi.org/10.1093/ecco-jcc/jjab232.250
https://doi.org/10.1093/ecco-jcc/jjab232.250
Autor:
I Chivato Martín Falquina, R M Saiz Chumillas, L Arias Garcia, B Vicente González, N Revilla Cuesta, L Alba Hernández, L Andrés Pascual, B Sicilia Aladrén
Publikováno v:
Journal of Crohn's and Colitis. 16:i544-i545
Background Intravenous (IV) infliximab is a first line treatment for moderate or severe flare of inflammatory bowel disease. Recently a new formulation of infliximab with subcutaneous (SC) administration has been developed and approved for this indic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::887be1d09966f4be31b1c137b8a72c90
https://doi.org/10.1093/ecco-jcc/jjab232.743
https://doi.org/10.1093/ecco-jcc/jjab232.743
Autor:
I Chivato Martín-Falquina, L Alba Hernández, M L Arias García, E Badia Aranda, R M Saiz Chumillas, B Sicilia Aladrén
Publikováno v:
Journal of Crohn's and Colitis. 15:S400-S401
Background The efficacy of ustekinumab in patients with Crohn’s disease (CD) refractory to anti-TNF is worse than in anti-TNF naïve patients. Methods Retrospective study of patients with CD refractory or intolerant to TNF initiating ustekinumab be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe353ff7a5df09e00b387acb1253df31
https://doi.org/10.1093/ecco-jcc/jjab076.513
https://doi.org/10.1093/ecco-jcc/jjab076.513
Autor:
E Sainz, M Calafat, B Botella Mateu, P Vega Villaamil, E Iyo, I Gonzalez Partida, A Caballero Mateos, Liczandro Hernandez, L Melcarne, C Calviño Suárez, Agnès Fernández-Clotet, H Alonso Galan, L Cuevas del Campo, P Perez Galindo, A López Sanromán, M Marques Cami, A López-García, M D Martin-Arranz, C Rubín de Célix, E Gonzalez Peña, Beatriz Sicilia, M C Rodriguez Grau, B Castro Senosiain, Francisco Mesonero, C Suarez Ferrer, Iria Bastón-Rey, J L Rueda García, M. Barreiro-de Acosta, Florina Ramírez, A Elosua Gonzalez, B Gomez Pastrana, R M Saiz Chumillas, C.Y. Rodríguez Díaz, R Plaza Santos, B Caballol, M. Mañosa Ciria
Publikováno v:
Journal of Crohn's and Colitis. 15:S363-S364
Background Biological drugs are being increasingly used for the treatment of inflammatory bowel diseases (IBD) in elderly patients. Despite the particular characteristics of this population subgroup, the efficacy and safety of these treatments in rea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dda8646bbe4a08114cafa7d0c6b89c0e
https://doi.org/10.1093/ecco-jcc/jjab076.462
https://doi.org/10.1093/ecco-jcc/jjab076.462